Gastric Cancer: Andecaliximab Plus Nivolumab Phase II Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Phase II Trial Results
- March 6, 2019
On January 17-19, 2019, at ASCO Gastrointestinal Cancers Congress, Dr. Manish A. Shah presented Phase II trial results evaluating andecaliximab (anti-MMP-9 monoclonal antibody) combined with nivolumab versus nivolumab alone in gastric and gastroesophageal junction adenocarcinoma.
Trial Design
Patient Population: Previously untreated unresectable/recurrent gastric and gastroesophageal junction adenocarcinoma
Treatment Arms:
- Andecaliximab + Nivolumab
- Nivolumab monotherapy
Primary Endpoints: Response rate, progression-free survival, overall survival
Key Results
Efficacy Comparison: No significant statistical difference between combination and monotherapy arms
Response Rate: Similar between andecaliximab + nivolumab and nivolumab alone
Progression-Free Survival: No improvement with combination
Overall Survival: No benefit with combination approach
Efficacy in Previously Treated Population
While combination therapy showed modest trends in previously treated, recurrent, and gastroesophageal junction patient subsets, differences did not achieve statistical significance.
Clinical Conclusions
Phase II data do not support additional benefit from andecaliximab addition to nivolumab in gastric cancer, with monotherapy remaining preferred approach.
Data Source
ASCO Gastrointestinal Cancers Congress 2019, Abstract No. 75
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4